Key intracellular pathway and epigenetic targets and potential therapies
| Category . | Target . | Potential agents . |
|---|---|---|
| BTK inhibitors | BTK | Ibrutinib |
| BTK | Acalabrutinib | |
| BTK | ONO/GS-4059 | |
| BTK | BGB-3111 | |
| BTK | CC-292 | |
| PI3K inhibitors | PI3Kδ | Idelalisib |
| PI3K δ and γ | Duvelisib | |
| PI3K δ and α | Copanlisib | |
| PI3Kδ | TGR1202 | |
| Syk inhibitors | Syk | Fostamatinib* |
| Syk | Entospletinib | |
| BCL2 inhibitors | BCL2 | Venetoclax |
| MDM2 inhibitors | MDM2 | Idasanutlin |
| MDM2 | DS-3032b | |
| Epigenetic modifiers | EZH2 | Tazemetostat |
| EZH2 | CPI-1205 | |
| EZH2 | GSK2816126 |
| Category . | Target . | Potential agents . |
|---|---|---|
| BTK inhibitors | BTK | Ibrutinib |
| BTK | Acalabrutinib | |
| BTK | ONO/GS-4059 | |
| BTK | BGB-3111 | |
| BTK | CC-292 | |
| PI3K inhibitors | PI3Kδ | Idelalisib |
| PI3K δ and γ | Duvelisib | |
| PI3K δ and α | Copanlisib | |
| PI3Kδ | TGR1202 | |
| Syk inhibitors | Syk | Fostamatinib* |
| Syk | Entospletinib | |
| BCL2 inhibitors | BCL2 | Venetoclax |
| MDM2 inhibitors | MDM2 | Idasanutlin |
| MDM2 | DS-3032b | |
| Epigenetic modifiers | EZH2 | Tazemetostat |
| EZH2 | CPI-1205 | |
| EZH2 | GSK2816126 |
No longer in development in NHL.